New treatment strategy with bone marrow-derived mesenchymal stem cells for obstructive nephropathy

间充质干细胞（MSCs）治疗慢性梗阻性肾纤维化的效果以前没有被评估过。左输尿管梗阻大鼠注射荧光标记的人和大鼠骨髓来源的间充质干细胞。3天至4周后，取肾，分析肾皮质干细胞浸润、上皮-间质转化（EMT）、肾纤维化、细胞因子和生长因子活性的证据。梗阻后4周以上肾间质中检测到间质干细胞。间充质干细胞对梗阻诱导的EMT和慢性肾纤维化具有保护作用。虽然MSCs在梗阻期间诱导肾保护的机制尚不清楚，但外源性MSCs降低了梗阻诱导的tnf - α水平，但没有改变tgf - β 1、VEGF、IL-10、FGF、HGF的表达。

The effect of mesenchymal stem cells (MSCs) therapy on chronic obstruction-induced renal fibrosis has not previously been evaluated. Rats with left ureteral obstruction underwent injection of fluorescent-labeled human and rat bone marrow-derived MSCs. From 3 days to 4 weeks later, the kidneys were harvested and the renal cortex analyzed for evidence of stem cell infiltration, epithelial-mesenchymal transition (EMT), renal fibrosis, and cytokine and growth factor activity.MSCs were detected in the interstitium of the kidney more than 4 weeks post-obstruction. MSCs provided protection against obstruction-induced EMT and chronic renal fibrosis. While the mechanism of MSCs-induced renal protection during obstruction remains unclear, exogenous MSCs reduced obstruction-induced TNF-alpha levels, but did not alter TGF-beta1, VEGF, IL-10, FGF, HGF expression.